ReviewMolecular biology reports2026
Immunoglobulins in recurrent pregnancy loss: Emerging biomarkers and therapeutic targets.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pregnancy loss (RPL) is a multifactorial reproductive disorder that affects approximately 1-5% of couples of reproductive age and is associated with considerable emotional and clinical burden. Although several genetic, anatomical, endocrine, infectious, and thrombophilic factors have been implicated, the underlying cause remains unexplained in nearly half of all cases, highlighting the importance of immune dysregulation in disease pathogenesis. Among immune factors, immunoglobulins play pivotal roles in maintaining maternal-fetal immune homeostasis by regulating immune tolerance, complement activation, autoantibody production, and inflammatory signalling. However, dysregulated humoral immune responses may disrupt placental development and fetal tolerance, thereby contributing to pregnancy failure. This review summarises current evidence regarding the biological functions of immunoglobulins in normal pregnancy and their involvement in the pathogenesis of RPL. We discuss the clinical significance of immunoglobulin-associated biomarkers, including antiphospholipid, antinuclear, anti-thyroid, and other pregnancy-related autoantibodies, and evaluate their utility in risk stratification and diagnosis. Emerging immunoglobulin-based therapeutic strategies, particularly intravenous immunoglobulin (IVIG), are reviewed in the context of current clinical evidence and guideline recommendations. Finally, we highlight the potential of comprehensive immunoglobulin profiling, integrated with clinical and molecular biomarkers, to support precision medicine approaches for individualised diagnosis, prognosis, and therapeutic decision-making in women with RPL. Continued mechanistic and translational research will be essential to validate these biomarkers and optimise personalised immunomodulatory interventions for improving pregnancy outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.